Pregabalin Capsule
Product Images NDC 71335-1790

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351790)

Label for Pregabalin 50 mg (CV) Capsule by Bryant Ranch Prepack. The label indicates the capsule is white and compares to Lyrica 50 mg (CV) Capsule by Hetero Labs Limited. Storage instructions specify room temperature of 20°-25°C (68°-77°F). The package count is 30 capsules. The label includes a barcode and NDC 71335-1790-1.*

FDA Label Image

Label (Lbl7133517902)

Pregabalin Capsules 50 mg oral dosage form label by Bryant Ranch Prepack. The label shows the active ingredient strength 50 mg, NDC 71335-1790-01, and packaging quantity of 30 capsules. Storage instructions indicate controlled room temperature between 20° to 25° C with permitted excursions. The label includes a barcode and the BRP Pharmaceuticals logo.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at various dosages (25 mg, 100 mg, and 200 mg taken three times a day) compared to placebo. The graph shows multiple curves illustrating patient response across different levels of pain improvement percentages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A survival curve graph comparing the estimated percentage of subjects without LTR (likely loss to relapse or related event) over a period of 180 days between Pregabalin and placebo groups. The x-axis represents days from 0 to 180, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Pregabalin shows higher percentages without LTR compared to placebo throughout the timeline.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line chart comparing the percent of subjects improved over various percentages of improvement from baseline to Week 12 BOCF for Pregabalin versus Placebo. The vertical axis shows the percent of subjects improved, and the horizontal axis shows the percent improvement from baseline to Week 12 BOCF. Pregabalin consistently shows higher improvement percentages than placebo across the range.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph depicting the percentage of subjects improved over time from baseline to Week 16, comparing Pregabalin and Placebo. The x-axis represents time intervals in weeks and days, and the y-axis shows the percentage of subjects improved. Two lines represent the results for Pregabalin and Placebo treatments.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The x-axis represents percent improvement in pain and the y-axis shows the percent of patients improved.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. The graph compares the effects of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day with a placebo, displaying four distinct trend lines for each group.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved. It shows three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating the relationship between dosage and patient response over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares three treatment groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar graph comparing the responder rates (%) across different dosages of a drug and placebo in two studies, labeled Study E1 and Study E3. The x-axis shows treatment groups including placebo and various doses, while the y-axis represents responder rate percentages. Statistically significant differences from placebo are indicated.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing seizure reduction (median % change from baseline) versus dose (mg/day) for Pregabalin. Four studies with different dosing schedules (BID, TID) are represented by various symbols. The graph highlights statistically significant reductions in seizures at increasing doses up to 600 mg/day, with p-values provided for significance.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing the percentage of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. Four lines represent different groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and Placebo. The graph illustrates relative patient improvement at various pain reduction thresholds.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of the active ingredient pregabalin showing its molecular arrangement with labeled functional groups including amine and carboxylic acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.